FDA accepts BioCardia Helix catheter pre-submission package

The U.S. Food and Drug Administration has accepted BioCardia, Inc.'s pre-submission package for the marketing clearance of its Helix catheter, a device intended for the delivery of therapeutic and diagnostic agents to the heart. The Sunnyvale, California-based company, listed on the Nasdaq under the ticker BCDA, stated that this acceptance follows a revised submission in September 2026 that incorporated advice from the FDA's Center for Devices and Radiological Health. In May 2026, BioCardia and the FDA reviewed an initial De Novo pre-submission package and agreed on two pathways for marketing clearance. The FDA raised no concerns regarding the product's safety data, performance, or compatibility with general classes of agents during that review. In August 2026, the FDA confirmed and accepted the meeting minutes from those discussions.

BioCardia expects the FDA to conduct a substantive review with written feedback, followed by a meeting to discuss approval via the De Novo pathway, within this quarter. The company noted that clinical data from fifteen trials involving nearly 500 patients provides a safety profile that could help the FDA ensure follow-on catheters demonstrate similar levels of safety and clinical experience to obtain clearance.

The Helix transendocardial delivery catheter is designed as an enabling platform for minimally invasive targeted delivery of agents intramyocardially. It features a specialized small distal helical needle that engages heart tissue from within the chamber to provide stability during delivery in a beating heart. BioCardia stated that marketing clearance of Helix could broaden its role as a delivery partner for companies developing experimental cellular, genetic, or protein-based treatments that require precise administration to cardiac tissue. The company also develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, including its CardiAMP autologous and CardiALLO allogeneic cell therapy platforms.

The press release includes forward-looking statements regarding intentions, beliefs, and projections that are subject to risks and uncertainties. These factors include the inherent uncertainties of developing new technologies, regulatory approvals, unexpected expenditures, and the ability to raise additional funding. BioCardia noted that its liquidity position and ability to progress clinical trials are among the factors that could cause actual results to differ materially from forward-looking statements. Additional risk factors are detailed in the company's Form 10-K filed with the Securities and Exchange Commission on March 26, 2026, and in subsequent quarterly reports.